Treatment of cachexia in oncology

Indian Journal of Palliative Care

Volumn 16, Issue 3, 2010, Pages 129-137

  Tazi, E M ^a   Errihani, H ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

Author keywords

Cachexia; Oncology; Treatment

Indexed keywords

EID: 78650641328     PISSN: 09731075     EISSN: 19983735     Source Type: Journal    
DOI: 10.4103/0973-1075.73643     Document Type: Review

References (64)

1. Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge D, et al. Cachexia: A new defnition. Clin Nutr 2008;27:793-9.
2. Thomas DR. Loss of skeletal muscle mass in aging: Examining the relationship of starvation, sarcopenia and cachexia. Clin Nutr 2007;26: 389-99.
3. Boddaert MS, Gerritsen WR, Pinedo HM. On our way to targeted therapy for cachexia in cancer? Curr Opin Oncol 2008;18:335-40.
4. Loprinzi CL, Ellison NM, Schaid DJ, Krook JE, Athmann LM, Dose AM, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1998;82:1127-32.
5. Loprinzi CL, Kugler J W, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fuoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-306.
6. Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, et al. Dronabinol versus megestrol acetate versus combination therapy for cancerassociated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 2002;20:567-73.
7. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001;61:499-514.
8. Mantovani G, Macciò A, Bianchi A, Curreli L, Ghiani M, Santona MC, et al. Megestrol acetate in neoplastic anorexia/cachexia: Clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995;25:135-41.
9. Mantovani G, Macciò A, Esu S, Lai P, Santona MC, Massa E, et al. Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Eur J Cancer 1999;33:602-7.
10. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: A randomized, placebo-controlled trial. Cancer 1998;82:553-60.
11. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev 2005;CD004310.
12. Femia RA, Goyette RE. The science of megestrol acetate delivery: Potential to improve outcomes in cachexia. BioDrugs 2005;19:179-87.
13. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607-9.
14. Willox JC, Corr J, Shaw J, Richardson M, Calman KC, Drennan M. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984;288:27.
15. Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, et al. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut 2003;52:1479-86.
16. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 2004;22:2469-76.
17. Fearon KC, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, et al. Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401-7.
18. Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fsh oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007;CD004597
19. Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, et al. Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394-400.
20. Jatoi A, Alberts SR, Foster N, Morton R, Burch P, Block M, et al. Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer 2005;13:381-6.
21. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, et al. A multicenter, phase II study of infiximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008;6:18-25.
22. Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM. Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial. Gut 2005;54:540-5.
23. Lai V, George J, Richey L, Kim HJ, Cannon T, Shores C, et al. Results of a pilot study of the effects of celecoxib on cancer cachexia in patients with cancer of the head, neck, and gastrointestinal tract. Head Neck 2008;30:67-74.
24. DeBoer MD. Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 2008;24:806-14.
25. Strasser F, Lutz TA, Maeder MT, Thuerlimann B, Bueche D, Tschöp M, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: A randomised, placebo-controlled, doubleblind, double-crossover study. Br J Cancer 2008;98:300-8.
26. Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:2832-6.
27. Garcia J. A phase II randomized, placebo-controlled, double-blind study of the effcacy and safety of RC-1291 (RC) for the treatment of cancer cachexia. J Clin Oncol 2007;25:5679-88.
28. Lundholm K, Körner U, Gunnebo L, Sixt-Ammilon P, Fouladiun M, Daneryd P, et al. Insulin treatment in cancer cachexia: Effects on survival, metabolism, and physical functioning. Clin Cancer Res 2007;13:2699-706.
29. Laviano A, Muscaritoli M, Cascino A, Preziosa I, Inui A, Mantovani G, et al. Branched-chain amino acids: The best compromise to achieve anabolism? Curr Opin Clin Nutr Metab Care 2005;8:408-14.
30. Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 2007;407:113-20.
31. van Norren K, Kegler D, Argilés JM, Luiking Y, Gorselink M, Laviano A, et al. Dietary supplementation with a specifc combination of high protein, leucine, and fsh oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 2009;100:713-22.
32. Lesser G, Case D, Ottery F, et al. ASCO Meeting. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on lean body mass (LBM), weight (wt) and quality of life (QOL) in patients with solid tumors and weight loss receiving chemotherapy. Proc Am Soc Clin Onc 2008;26:505s.
33. Braiteh F, Dalal S, Khuwaja A, David H, Bruera E, Kurzrock R. Phase I pilot study of the safety and tolerability of olanzapine (OZA) for the treatment of cachexia in patients with advanced cancer. J Clin Oncol 2008;26:196-203
34. Argiles JM, Lopez-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discov Today 2008;13:73-8.
35. Cerchietti LC, Navigante AH, Peluffo GD, Diament MJ, Stillitani I, Klein SA, et al. Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: A pilot study. J Pain Symptom Manage 2004;27:85-95.
36. Cerchietti LC, Navigante AH, Castro MA. Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fsh oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutr Cancer 2007;59:14-20.
37. Mantovani G, Madeddu C, Macciò A, Gramignano G, Lusso MR, Massa E, et al. Cancer-related anorexia/cachexia syndrome and oxidative stress: An innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004;13:1651-9.
38. Mantovani G, Macciò A, Madeddu C, Gramignano G, Lusso MR, Serpe R, et al. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anticyclooxygenase- 2 showing effcacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. Cancer Epidemiol Biomarkers Prev 2006;15:1030-4.
39. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, et al. The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: Correlation with disease progression. Free Radic Res 2003;37:213-23.
40. Mantovani G, Macciò A, Madeddu C, Mura L, Gramignano G, Lusso MR, et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: Assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med 2003;81:664-73.
41. Mantovani G, Macciò A, Madeddu C, Mura L, Massa E, Gramignano G, et al. Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: Impact of an antioxidant treatment. J Environ Pathol Toxicol Oncol 2003;22:17-28.
42. Mantovani G, Madeddu C, Gramignano G, Lusso MR, Mocci M, Massa E, et al. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: Phase II study evaluating clinical, quality of life, and laboratory parameters. J Exp Ther Oncol 2003;3:205-19.
43. Mantovani G, Macciò A, Madeddu C, Mulas C, Massa E, Astara G, et al. Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. Oncol Rep 2002;9:887-96.
44. Mantovani G, Macciò A, Madeddu C, Serpe R, Massa E, Gramignano G, et al. Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: Potential mechanisms for its activity. J Exp Ther Oncol 2004;4:69-78.
45. Higdon J V, Frei B. Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003;43: 89-143.
46. Beller E, Tattersall M, Lumley T, Levi J, Dalley D, Olver I, et al. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: A randomised placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol 1997;8: 277-83.
47. Bruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279-82.
48. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, et al. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-74.
49. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-7.
50. Barber MD, Wigmore SJ, Ross JA, Fearon KC. Eicosapentaenoic acid attenuates cachexia associated with advanced pancreatic cancer. Prostaglandins Leukot Essent Fatty Acids 1997;57:204.
51. Falconer JS, Ross JA, Fearon KC, Hawkins RA, O'Riordain MG, Carter DC. Effect of eicosapentaenoic acid and other fatty acids on the growth in vitro of human pancreatic cancer cell lines. Br J Cancer 1994;69:826-32.
52. Beck SA, Smith KL, Tisdale MJ. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res 1991;51:6089-93.
53. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fsh oil on weight-loss in patients with pancreatic cancer. Br J Cancer 1999;81:80-6.
54. Pettegrew J W, Levine J, McClure RJ. Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 2000;5:616-32.
55. Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, et al. Randomized phase III clinical trial of fve different arms of treatment for patients with cancer cachexia: Interim results. Nutrition 2008;24:305-13.
56. Trikha M, Corringham R, Klein B, Rossi JF. Targeted antiinterleukin- 6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-65.
57. Figueras M, Busquets S, Carbó N, Barreiro E, Almendro V, Argilés JM, et al. Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett 2004;569:201-6.
58. Harcourt LJ, Holmes AG, Gregorevic P, Schertzer JD, Stupka N, Plant DR, et al. Interleukin- 15 administration improves diaphragm muscle pathology and function in dystrophic mdx mice. Am J Pathol 2005;166:1131-41.
59. Fuster G, Busquets S, Ametller E, Olivan M, Almendro V, de Oliveira CC, et al. Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists. Cancer Res 2007;67:6512-9.
60. Evans W, Smith M, Morley J, et al. Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients. J Clin Oncol 2007;25:4536-41
61. Acharyya S, Guttridge DC. Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clin Cancer Res 2007;13:1356-61.
62. Deboer MD, Marks DL. Cachexia: Lessons from melanocortin antagonism. Trends Endocrinol Metab 2006;17:199-204.
63. Tan BH, Deans DA, Skipworth RJ, Ross JA, Fearon KC. Biomarkers for cancer cachexia: Is there also a genetic component to cachexia? Support Care Cancer 2008;16:229-34.
64. Fearon KC. Cancer cachexia: Developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124-32.